Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report

Abstract Background Crizotinib is a multi-target inhibitor approved for the treatment of advanced non-small-cell lung cancer patients with a ROS1 rearrangement. However, interstitial lung disease is a rare but severe and fatal side effect of crizotinib that should lead to immediate discontinuation o...

Full description

Bibliographic Details
Main Authors: Shibo Wu, Kaitai Liu, Feng Ren, Dawei Zheng, Deng Pan
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Pulmonary Medicine
Subjects:
Interstitial lung disease
Crizotinib
ROS1 rearrangement
EGFR mutation
Online Access:http://link.springer.com/article/10.1186/s12890-018-0682-9

Internet

http://link.springer.com/article/10.1186/s12890-018-0682-9

Similar Items